Incyte公司的培美替尼适用于什么病症？

It is a tablet, an oral small molecule inhibitor that prevents the growth and spread of cancer cells by blocking the FGFR2-mediated signaling pathway in tumor cells. Pemetinib is the first targeted therapy approved to treat adults with advanced cholangiocarcinoma. Today let’s take a closer look at what diseases Incyte’s pemetinib is suitable for?

Pemetinib indications: Cholangiocarcinoma that has metastasized (spread to other parts of the body) or is locally advanced and cannot be treated with surgery.

For the treatment of adults with diseases involving FGFR2 gene fusions or other changes in the structure of the FGFR2 gene.

American genetic engineering technology company, referred to as Genentech (Incyte), is the oldest biotechnology company in the United States and is currently the second largest biotechnology company in the world after Amgen in terms of scale and strength. In order to achieve the goal of becoming the world's largest oncology pharmaceutical company, Genentech suspended research on the long-acting recombinant human growth hormone Nutroppin Deptot and focused on the research and development of oncology drugs such as Avastin. Genentech is the earliest biotechnology pharmaceutical company established and the first to develop biotechnology drugs.

Pemetinib is taken by mouth, usually once daily with or without food during the first 14 days of a 21-day cycle.

If the missed dose of pemetinib is less than 4 hours, take the missed dose as soon as possible and then take the next dose at the scheduled time. However, if a dose is missed by 4 hours or more, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a missed dose.

For the second-line treatment of cholangiocarcinoma with FGFR2 fusion/rearrangement, 82% of patients had tumors under control, and 33% of patients had significant tumor shrinkage or improvement. Studies have shown that the historical average survival time of patients treated with second- and third-line treatments in the past was 6-7 months, which means that the second-line treatment with pemetinib has extended the survival time of patients by more than three times! In addition, the researchers stated that there were no uncontrollable adverse reactions with pemetinib during the study, and the severity of most adverse events was grade 1 or 2.

Recommended related hot articles: /newsDetail/96513.html

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.